Seeking Alpha

Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal ...

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (BMY) (NYSE: BMY) today announced that the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an investigational cereblon E3 ligase modulator ...
ascopubs.org

A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy: Results from the MD Anderson INTERCEPT Program.

Amivantamab monotherapy in relapsed/refractory metastatic colorectal cancer: OrigAMI-1, an open-label, phase 1b/2 study. This is an ASCO Meeting Abstract from the 2024 ASCO Gastrointestinal Cancers ...
ascopubs.org

A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy compared to synthetic control cohort: Results ...

Clinical validation of Histotype Px Colorectal in patients in a U.S. colon cancer cohort. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full ...